scPharmaceuticals (NASDAQ:SCPH) Cut to Hold at Maxim Group

Maxim Group downgraded shares of scPharmaceuticals (NASDAQ:SCPH) from a buy rating to a hold rating in a research report released on Monday, Marketbeat reports.

Separately, Wall Street Zen raised scPharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, August 9th. One investment analyst has rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $12.00.

scPharmaceuticals Trading Down 0.2%

Shares of NASDAQ:SCPH opened at $5.52 on Monday. The stock has a 50 day moving average of $4.68 and a 200 day moving average of $3.61. The company has a market cap of $294.22 million, a PE ratio of -3.05 and a beta of 0.40. The company has a current ratio of 3.85, a quick ratio of 3.14 and a debt-to-equity ratio of 3.86. scPharmaceuticals has a 12-month low of $1.94 and a 12-month high of $6.28.

scPharmaceuticals (NASDAQ:SCPH) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.04). The company had revenue of $16.04 million for the quarter, compared to the consensus estimate of $15.41 million. scPharmaceuticals had a negative net margin of 183.55% and a negative return on equity of 1,647.86%. As a group, equities research analysts expect that scPharmaceuticals will post -1.53 EPS for the current year.

Institutional Trading of scPharmaceuticals

Hedge funds have recently modified their holdings of the company. Police & Firemen s Retirement System of New Jersey raised its holdings in shares of scPharmaceuticals by 63.6% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 9,336 shares of the company’s stock worth $36,000 after acquiring an additional 3,628 shares in the last quarter. Moss Adams Wealth Advisors LLC purchased a new stake in shares of scPharmaceuticals during the 2nd quarter worth approximately $38,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new stake in shares of scPharmaceuticals during the 2nd quarter worth approximately $41,000. Walleye Capital LLC purchased a new stake in shares of scPharmaceuticals during the 2nd quarter worth approximately $43,000. Finally, Assenagon Asset Management S.A. purchased a new stake in shares of scPharmaceuticals during the 1st quarter worth approximately $33,000. 89.52% of the stock is owned by hedge funds and other institutional investors.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.